ACMA prioritizes ESG issues, underscoring our unwavering commitment to sustainability, ethical business practices, and corporate responsibility on a global scale
We believe that organizations like the ACMA play a crucial role in addressing the complex healthcare challenges facing our global community. Our commitment to Environmental, Social, and Governance (ESG) issues is integral to our mission and operations. We recognize that sustainable practices, ethical decision-making, and social responsibility are not just add-ons, but fundamental to our success and impact in the life sciences sector.
William Soliman, CEO at ACMA
The ACMA believes that raising the standards in healthcare and the pharmaceutical industry ultimately serves the public good, helps empower people and establishes a roadmap for continued improvement in society for generations to come.
Health Equity
Through training and awareness on diversity and inclusion in clinical trials, ensuring compliance and ethical interactions with healthcare providers and the ACMA believes that we can improve health equity issues through education and social awareness.
Diversity & Inclusion
ESG addresses issues not only related to the environment, but also focuses on social responsibility. For years, clinical trials have neglected the differences in response to therapy among patients with diverse backgrounds. The ACMA offers a training program for life sciences professionals on diversity and inclusion in clinical trials.
Accountability
Pharmaceutical manufacturers have a tremendous responsibility to serve the public good. Pharmaceutical companies have been the major drivers of important inventions and progress in medicine over the last 200 years. Starting with penicillin and life saving drugs for patients with cancer, HIV and Hepatitis C, pharmaceutical companies need to be trusted by the public. Unfortunately, this has not always been the case. The ACMA believes that commitment to ESG helps improve trust among patients and healthcare providers.
Harmonization and standardization within the life sciences industry such as that provided through certification and credentialing of pharmaceutical industry professionals helps address the industry's health equity issues we face today.
Patients at large need leaders with expertise to execute much needed social responsibility to better address disparities such as gaps in the underrepresentation of minorities in clinical trials.